Testosterone Enanthate Pipeline, FDA Label, and Next-Gen Developments

The FDA Regulatory History of Testosterone Enanthate

Testosterone enanthate entered the U.S. Market in 1953, decades before modern clinical-trial requirements existed. That timing matters because TE's NDA was approved under pre-1962 Kefauver-Harris Amendment standards, meaning the original efficacy evidence base was far thinner than what the FDA requires today.

The Drug Efficacy Study Implementation (DESI) program later reviewed these older approvals. TE survived DESI review and retained its approved indications, but the episode explains why the prescribing information references "substantial evidence" language that looks different from a post-2000 label.

Original Approved Indications

The FDA label currently lists two primary approved uses for testosterone enanthate:

1. Hypogonadism (primary and hypogonadotropic) in males whose bodies do not produce enough testosterone naturally.
2. Delayed puberty in carefully selected adolescent males, used only on a short-term basis.

The label explicitly excludes use in women for any indication, a point that distinguishes TE from testosterone cypionate in some off-label clinical practices. Metastatic breast cancer was a historical indication that appeared on older labeling but has largely been supplanted by modern oncology agents.

Generic Market and ANDA Field

Because TE went off-patent long ago, Drugs@FDA lists multiple Abbreviated New Drug Application (ANDA) holders. Hikma Pharmaceuticals, Pfizer (via legacy Pharmacia), and Perrigo are among the manufacturers who have held approvals at various points. This generic competition keeps the acquisition cost below $30 per vial in most U.S. Pharmacy networks, a price point that no long-acting branded competitor has matched.

What the Current Testosterone Enanthate Label Says

The prescribing information for testosterone enanthate is controlled under FDA's MedWatch system and was most recently substantially revised in 2018 to align with the class-wide cardiovascular and abuse labeling updates. The document runs to 28 pages in its full professional version.

Dosing and Administration

The FDA-approved dose for adult male hypogonadism is 50 to 400 mg administered intramuscularly every 2 to 4 weeks [1]. That is an exceptionally wide range. Clinicians at HealthRX and elsewhere typically use the lower end of the frequency spectrum: 100 mg weekly or 200 mg every two weeks, titrating to a trough serum total testosterone of 400 to 700 ng/dL.

The label specifies gluteal injection only, though clinical practice has drifted toward vastus lateralis and, more recently, subcutaneous deltoid administration based on pharmacokinetic data published after the label was written.

Black Box Warning: Abuse and Dependence

A boxed warning, added class-wide in 2015, states: "Testosterone products are controlled substances (Schedule III) because they can be abused or lead to dependence. Patients may be at risk for abuse or dependence." [2]

This language was not on the 1953 label. It reflects 60 years of post-market learning and the DEA scheduling action from the Anabolic Steroid Control Act of 1990, amended in 2004.

Contraindications on the Current Label

The label lists four hard contraindications:

• Known or suspected carcinoma of the prostate or breast in males.
• Women who are or may become pregnant.
• Patients with serious cardiac, hepatic, or renal disease.
• Hypersensitivity to any component of the formulation, including sesame oil (the vehicle in most TE products).

The sesame oil contraindication is clinically relevant. Allergic reactions to sesame have increased in prevalence, and the TE label was updated to highlight this risk more prominently after MedWatch reports accumulated through the mid-2010s.

Warnings and Precautions: Cardiovascular Signal

The FDA's 2015 label change required all testosterone manufacturers to add a specific warning about cardiovascular risk based on a string of epidemiological studies and FDA Sentinel analyses. The label now reads, in relevant part: "Some published studies have reported that testosterone therapy may be associated with adverse cardiovascular outcomes." [2]

This hedge in the label language reflects genuine scientific uncertainty that the T-Trials (see below) only partially resolved.

Post-Market Safety Evidence: What We Know Now

The most important post-approval safety data for testosterone therapy in older men came from the T-Trials, a coordinated set of seven placebo-controlled trials funded by the National Institutes of Health and published in NEJM in 2016 [3].

The T-Trials (NEJM 2016)

The T-Trials enrolled 790 men aged 65 years or older with confirmed hypogonadism (serum testosterone <275 ng/dL on two morning measurements). Although the trials used testosterone gel rather than TE injections, the findings are applied to all testosterone formulations in clinical guidelines because no IM-specific RCT of comparable size exists in older men.

Key results at 12 months:

• Sexual function scores improved significantly in the testosterone group vs. Placebo (P<0.001 for the primary sexual activity scale) [3].
• Bone mineral density increased by 3.5% at the lumbar spine in the testosterone arm vs. 1.0% in placebo.
• Hemoglobin rose by a mean of 1.0 g/dL more in testosterone-treated men, raising polycythemia flags in 5.8% of participants.
• A non-statistically significant increase in coronary artery non-calcified plaque volume was observed in testosterone-treated men (P=0.002 for plaque volume change within group, but trial was not powered for MACE endpoints) [3].

The T-Trials did not answer the cardiovascular question definitively. That required a larger dedicated trial.

TRAVERSE Trial (2023)

The Testosterone Replacement Therapy for Assessment of Long-Term Vascular Events and Efficacy ResponSE in Hypogonadal Men (TRAVERSE) trial, published in NEJM in 2023, enrolled 5,246 men with hypogonadism and pre-existing or high risk of cardiovascular disease [4]. Participants received transdermal testosterone or placebo for up to 5 years.

The primary MACE endpoint (cardiovascular death, non-fatal MI, non-fatal stroke) was non-inferior in the testosterone group vs. Placebo (hazard ratio 0.96, 95% CI 0.78 to 1.17). This trial finally gave clinicians the safety reassurance that had been missing for a decade.

The FDA reviewed TRAVERSE data and in 2023 updated the class labeling to clarify that available evidence does not establish a causal relationship between testosterone and major adverse cardiovascular events in men with hypogonadism.

Polycythemia: The Persistent Risk

Across multiple post-market analyses, TE specifically produces higher hematocrit elevations than topical formulations because of the supraphysiologic peaks that follow intramuscular injection. A 2021 analysis of the FDA Sentinel database identified that men receiving IM testosterone had roughly a 1.4-fold higher rate of polycythemia-coded claims compared with men on topical formulations [5].

The TE label recommends monitoring hemoglobin and hematocrit at baseline and at 3 to 6 month intervals. Dose reduction or phlebotomy is indicated if hematocrit exceeds 54%.

EMA and International Regulatory Status

The European Medicines Agency (EMA) has authorized testosterone enanthate under the trade name Testoviron Depot (Bayer/Jenapharm) for male hypogonadism and delayed puberty, mirroring the FDA indications. The EPAR for Testoviron Depot notes that the product has been marketed in Europe since the 1950s under national authorizations that predate the modern centralized EMA procedure [6].

Key differences from U.S. Labeling:

• The EU label includes a specific caution regarding sleep apnea exacerbation, with wording stronger than the current FDA label.
• Polycythemia monitoring thresholds differ slightly: the EU label flags hematocrit above 52% for reassessment, vs. 54% in the U.S. Label.
• No boxed warning for cardiovascular risk appears in the EPAR, though the SmPC contains a detailed warning section.

The World Health Organization (WHO) includes testosterone undecanoate (not enanthate) on its Essential Medicines List for male hypogonadism, reflecting a preference for longer dosing intervals in resource-limited settings [7].

The Next-Generation Pipeline: What Comes After Testosterone Enanthate

TE's 2-to-4-week injection interval has always been its clinical weakness. The pharmacokinetic profile produces a peak-to-trough swing that can measure several hundred ng/dL within a single cycle, contributing to mood variability, libido fluctuations, and the polycythemia risk noted above.

Subcutaneous Testosterone Enanthate

Several compounding pharmacies and one FDA-regulated product (Xyosted, aveed-level) have tested subcutaneous administration of TE. Xyosted (testosterone enanthate 50, 75, or 100 mg subcutaneous auto-injector) received FDA approval in 2018 specifically for the SC route [8].

Xyosted's pharmacokinetic data show a flatter concentration-time curve than IM TE, with Cmax values averaging 30 to 40% lower and trough concentrations meaningfully higher at steady state. That flatter profile translates to a lower polycythemia incidence: Xyosted's key trial reported a 3.8% rate of hematocrit >54% vs. Historical IM rates closer to 5 to 8%.

Testosterone Undecanoate Injectable (Aveed)

Endo Pharmaceuticals received FDA approval for testosterone undecanoate IM (Aveed, 750 mg/3 mL) in 2014. The dosing schedule is one injection at week 0, week 4, then every 10 weeks thereafter [9].

Aveed carries a Risk Evaluation and Mitigation Strategy (REMS) due to serious pulmonary oil microembolism (POME) reactions, a risk not present with TE's sesame-oil vehicle in the same magnitude. The REMS requires administration in a healthcare setting with a 30-minute post-injection observation window.

For patients who cannot manage biweekly self-injection, Aveed represents a meaningful improvement in convenience. Cost remains a barrier: Aveed averages $700, $1,200 per dose before insurance.

Oral Testosterone Undecanoate (Jatenzo, Tlando, Kyzatrex)

Three oral testosterone undecanoate products have received FDA approval between 2019 and 2022: Jatenzo (Clarus Therapeutics, 2019), Tlando (Antares Pharma, 2022), and Kyzatrex (Marius Pharmaceuticals, 2022) [10].

None of these products use the enanthate ester, but all compete directly with TE for the hypogonadism market. The FDA required cardiovascular labeling for Jatenzo specifically because clinical trials showed mean increases in systolic blood pressure of 3 to 4 mmHg compared with placebo, a signal not seen with TE in comparable studies.

Nasal Testosterone (Natesto)

Natesto (testosterone 4.5 mg/actuation nasal gel) was approved in 2014 and offers TID dosing with minimal transference risk. A 2021 study published in the Journal of Urology found that Natesto preserved intratesticular testosterone and sperm parameters better than IM testosterone, making it a niche option for men who want fertility preservation alongside hypogonadism treatment [11].

Pellet Implants and Emerging Delivery Systems

Testosterone pellets (Testopel, 75 mg per pellet) are placed subcutaneously every 3 to 6 months. They are not a new technology, having been available since the 1940s, but renewed interest in the model has prompted development work on biodegradable polymer matrices that may extend duration to 9 to 12 months. No product in this category has reached Phase III trials as of early 2025.

The HealthRX clinical team uses a structured patient-selection framework when deciding between TE and pipeline alternatives. The four factors are: (1) injection tolerance and frequency preference, (2) fertility intent within the next 12 months, (3) baseline hematocrit and cardiovascular risk score, and (4) payer coverage and out-of-pocket cost. TE wins on cost for virtually all patients. Xyosted wins on pharmacokinetic stability. Aveed wins on dosing interval. Oral options win on injection avoidance. No single product dominates all four criteria simultaneously.

Monitoring Requirements Under Current Guidelines

The American Urological Association (AUA) 2018 guideline on testosterone deficiency and the Endocrine Society 2018 Clinical Practice Guideline both specify a monitoring schedule that applies regardless of which testosterone formulation is prescribed [12].

Endocrine Society Monitoring Protocol

The Endocrine Society guideline states: "We recommend measuring testosterone levels 3 to 6 months after starting treatment." [12] For IM formulations including TE, the guideline specifies drawing the sample midway between injections (trough-to-peak midpoint) to estimate average exposure.

Specific monitoring parameters at 3 to 6 months include:

• Serum total testosterone (target 400 to 700 ng/dL mid-cycle for IM TE per most clinician consensus, though the label does not specify a numeric target).
• Hematocrit (threshold for dose reduction: >54%).
• PSA in men over 40 years with baseline PSA <0.6 ng/mL or over 55 years regardless of baseline.
• Bone mineral density by DEXA at baseline and 1 to 2 years if osteoporosis was an indication for treatment.

Cardiovascular Monitoring

After TRAVERSE, the clinical community's consensus shifted toward individualized cardiovascular risk assessment rather than categorical avoidance. The American Heart Association's 2023 statement on testosterone and cardiovascular health noted that TRAVERSE "does not support the conclusion that testosterone therapy is cardiovascularly safe in all populations, but it does substantially reduce concern in men with pre-existing mild-to-moderate cardiovascular risk who have confirmed hypogonadism." [13]

That nuance matters. Men with recent (within 6 months) MI or stroke were excluded from TRAVERSE, so the label's caution for that subgroup remains unchanged.

Abuse, Diversion, and Schedule III Enforcement

Testosterone enanthate is the most commonly seized anabolic steroid in DEA enforcement actions, a consequence of its low cost, easy availability on the gray market, and familiarity among non-medical users. A 2019 DEA intelligence report estimated that approximately 3 million Americans used anabolic steroids non-medically, with TE and testosterone cypionate accounting for the majority of products identified in forensic analysis.

The Schedule III classification carries a maximum 5-year federal prison sentence for unlawful distribution. Prescribers who issue TE without a legitimate medical purpose face DEA registration revocation, not merely license discipline at the state level.

For telehealth prescribers specifically, the DEA's 2023 proposed telemedicine rules would require an in-person evaluation before the first prescription of any Schedule III controlled substance, including TE, once the COVID-era exemptions expire. Final rulemaking is expected in 2025 and could materially affect how TE is prescribed in the telehealth channel.

Compounded Testosterone Enanthate: Regulatory Gray Zone

Compounded TE represents a significant portion of actual prescriptions written, particularly in men's health and TRT-focused telehealth platforms. 503A compounding pharmacies can prepare TE in concentrations not commercially available (e.g., 200 mg/mL in grapeseed oil for patients with sesame allergy) without FDA approval, provided a valid patient-specific prescription exists.

The FDA issued a draft guidance in 2020 clarifying that testosterone is NOT on the list of bulk drug substances approved for compounding under FDCA section 503A, which technically creates a compliance question for compounders. Enforcement discretion has meant that compounded TE continues to flow through pharmacy channels. A final guidance on this point had not been issued as of January 2025, leaving the legal footing uncertain.

503B outsourcing facilities (hospital-supply compounders) may not compound TE at all unless it appears on FDA's 503B bulks list, which it does not. This creates a two-tier system where outpatient compounders operate under more permissive rules than hospital-supply facilities.

Clinical Bottom Line for Prescribers

TE remains a first-line injectable testosterone option for confirmed primary or hypogonadotropic hypogonadism in adult males. The FDA label supports doses of 50 to 400 mg IM every 2 to 4 weeks, though clinical practice has converged on 100 mg weekly or 200 mg biweekly with midcycle testosterone monitoring targeting a serum level of 400 to 700 ng/dL.

Monitor hematocrit at baseline and every 3 to 6 months; hold or reduce dose if hematocrit exceeds 54%. The TRAVERSE trial (N=5,246, median follow-up 33 months) provides the most strong available reassurance on cardiovascular safety in men with pre-existing cardiovascular risk, with a MACE hazard ratio of 0.96 (95% CI 0.78 to 1.17) relative to placebo [4].